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Human sexual determination is initiated by a cascade of genes that lead to the development of the fetal gonad.Whereas development of
the female external genitalia does not require fetal ovarian hormones, male genital development requires the action of testicular testos-
terone and its more potent derivative dihydrotestosterone (DHT). The ‘‘classic’’ biosynthetic pathway from cholesterol to testosterone in
the testis and the subsequent conversion of testosterone to DHT in genital skin is well established. Recently, an alternative pathway
leading to DHT has been described in marsupials, but its potential importance to human development is unclear. AKR1C2 is an enzyme
that participates in the alternative but not the classic pathway. Using a candidate gene approach, we identified AKR1C2mutations with
sex-limited recessive inheritance in four 46,XY individuals with disordered sexual development (DSD). Analysis of the inheritance of
microsatellite markers excluded other candidate loci. Affected individuals had moderate to severe undervirilization at birth; when recre-
ated by site-directed mutagenesis and expressed in bacteria, the mutant AKR1C2 had diminished but not absent catalytic activities. The
46,XY DSD individuals also carry a mutation causing aberrant splicing in AKR1C4, which encodes an enzyme with similar activity. This
suggests amode of inheritance where the severity of the developmental defect depends on the number ofmutations in the two genes. An
unrelated 46,XY DSD patient carried AKR1C2mutations on both alleles, confirming the essential role of AKR1C2 and corroborating the
hypothesis that both the classic and alternative pathways of testicular androgen biosynthesis are needed for normal humanmale sexual
differentiation.Introduction
Male sexual determination is initiated by Y-chromosomal
SRY, which activates a cascade of genes that lead the
embryonic gonad to develop into a testis. Fetal testicular
Sertoli cells then produce Mullerian inhibitory substance,
which is responsible for the involution of the Mullerian
ducts. These ducts otherwise develop into the uterus,
fallopian tubes, and cervix. Fetal testicular Leydig cells
produce testosterone from cholesterol by the sequential
actions of enzymes encoded by CYP11A1 (MIM 118485),
CYP17A1 (MIM 609300), HSD3B2 (MIM 201810), and
HSD17B3 (MIM 605573) (Figure 1).1 Subsequent differenti-
ation of male external genitalia also requires the action of
dihydrotestosterone (DHT), produced from testicular
testosterone by the action of 5a-reductase, type 2 (encoded
by SRD5A2 [MIM 607306]) in genital skin.2 Genetic males
with disorders in the enzymes in this classic pathway of
androgen biosynthesis have disordered sexual develop-
ment with incompletely developed (‘‘ambiguous’’)
external genitalia, but some hormonal disorders of male
development remain unexplained, and this fact suggests
that not all relevant factors have been identified.3 Fetal
male marsupials produce DHT by an alternative biosyn-
thetic pathway without the intermediacy of testosterone
(Figure 1)4–6. Two disorders of human steroidogenesis
suggest that this alternative pathway might be involved
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The Americ21-hydroxylase deficiency (CAH1 [MIM 201910]) produce
amounts of 17-hydroxyprogesterone (17OHP) that are
typically elevated 100-fold,7 but 17OHP is not readily con-
verted to androstenedione and testosterone by the classic
pathway,8 yet affected females become severely virilized
in utero, and this suggests conversion of 17OHP to
dihydrotestosterone via the alternative pathway.9 Second,
patients with mutations in POR encoding P450 oxidore-
ductase (encoded by POR [MIM 124015, 613571, and
201750]), which donates electrons to steroid 21-hydroxy-
lase (CYP21A2), 17a-hydroxylase/17,20 lyase (P450c17,
CYP17A1), and aromatase (CYP19A1 [MIM 107910]), typi-
cally have ambiguous genitalia10,11 and excrete urinary
steroid metabolites that suggest involvement of the alter-
nate pathway.12–16 We explored the potential role of the
alternative pathway in human male development in five
patients from two families with genital ambiguity and
disordered androgen biosynthesis after mutations in the
classic pathway of steroid biosynthesis had been excluded.Subjects and Methods
Clinical Material
Family 1
A Swiss family that included three persons with ambiguous geni-
talia was first described in 1972 as having ‘‘17,20-desmolase defi-
ciency’’17. Two 46,XY cousins (Figure 2A, individuals III.3 and
III.4) had undervirilized external genitalia and cryptorchidism.rsity Children’s Hospital Bern, University of Bern, 3010 Bern, Switzerland;
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Figure 1. Synthesis of Dihydrotestosterone via the Classic and Alternative (Backdoor) Pathways
The classic pathway of steroidogenesis leading to dihydrotestosterone is shown on the left, and the alternative pathway is shown on the
right. The factors in the classic pathway are CYP11A1 (cholesterol side-chain cleavage enzyme, P450scc), StAR (steroidogenic acute regu-
latory protein), CYP17A1 (17a-hydroxylase/17,20-lyase, P450c17), HSD3B2 (3b-hydroxysteroid dehydrogenase, type 2), HSD17B3
(17b-HSD3 [17b-hydroxysteroid dehydrogenase, type 3] and 5a-reductase, type 2 [5a-reductase 2, encoded by SRD5A2]). The alternative
pathway is characterized by the presence of additional enzymes: 5a-reductase, type 1 (5a-reductase 1, encoded by SRD5A1), AKR1C2 3
(3a-reductase, type 3) and possibly AKR1C4 (3a-reductase, type 1) and RoDH (3-hydroxyepimerase, encoded byHSD17B6). Most steroids
are identified by their trivial names; 17-hydroxy-dihydroprogesterone (17OH-DHP) is 5a-pregnane-17a-ol-3,20-dione; 17-hydroxy-allo-
pregnanolone (17OH-allo) is 5a-pregnan-3a,17a-diol-20-one; 5a-dihydroprogesterone (5a-DHP) is 5a-pregnane-3,20-dione, and allo-
pregnanolone is 3a-hydroxy-dihydroprogesterone (3a-OH-DHP) or 5a-pregnane-3a-ol-20-one.Analyses of urinary steroids at that time showed increased
excretion of pregnenetriol (a urinary metabolite of 17-hydroxy-
pregnenolone) and pregnanetriolone (a metabolite of 21-deoxy-
cortisol), which was also hyperresponsive to stimulation with
either chorionic gonadotropin or corticotropin. Excretion of preg-
nanetriol (a metabolite of 17-hydroxyprogesterone) was modestly
elevated, hyperresponsive to corticotrophin, and unresponsive
to chorionic gonadotropin. Normal total excretion of etiocholano-
lone, androsterone, and other steroids requiring 5a-reduction
(e.g., 5a-tetrahydrocortisol), and their ratios excluded 5a-reduc-
tase deficiency. Metabolites of cortisol and cortisone were
normal, but urinary dehydroepiandrosterone was unmeasureable
after stimulation with chorionic gonadotropin or corticotropin.
A maternal aunt (II.5) had tall stature, slightly virilized genitalia,
and primary amenorrhea. Her karyotype was 46,XY; a laparatomy
revealed no uterus, and gonadectomy revealed normal testicular
tissue.
Individual III.1 was SRY-negative and had normal female
external genitalia and a sonographically detectable uterus. Indi-
vidual III.2 had normal female external genitalia but had steroidal
responses to chorionic gonadotropin and corticotropin that were
similar to individuals III.3 and III.4 suggesting she had the same
defect in steroidogenesis. Her karyotype was 46,XY, and she had
no uterus. She was gonadectomized before puberty and histology
showed normal (not dysgenetic) testicular tissue. No family
members had signs or steroidal findings of adrenal insufficiency.
Individuals II.5 and III.2 underwent gonadectomy in the 1970s
and declined further investigations of adrenal steroidogenesis.202 The American Journal of Human Genetics 89, 201–218, August 1Family 2
This Swiss patient was diagnosed with 46,XY disordered sexual
development (DSD) during surgery for bilateral inguinal hernias
at the age of 7 weeks. Normal looking testes were found intraoper-
atively in a completely feminized subject without evidence of
Mu¨llerian structures. Chromosome analysis revealed a 46,XY
karyotype. There was no evidence of additional 46,XY DSD cases
in the family. Laparascopic gonadectomy was carried out at 2 years
of age. No further hormonal assessment was performed in this
patient. The phenotype of 46,XY patients of both families is
summarized in Table S1, available online.
Mutation Analysis
After obtaining informed consent from the studied subjects,
genomic DNA was extracted from peripheral blood leukocytes
(PBL) (QIAGEN DNA blood and cell culture kit; QIAGEN
GmbH, Hilden, Germany). The genes for steroidogenic factor 1
(NR4A1, NM_004959.4 [MIM 184757]), androgen receptor (AR,
NM_000044.2, NM_00101165.1 [MIM 313700]), 17a-hydroxy-
lase/17,20 lyase (CYP17A1, NM_000102.3), P450 oxidoreductase
(POR,NM_000941.2), and 3-hydroxyepimerase (RoDH/HSD17B6,
NM_003725.2 [MIM 606623]) were sequenced in all patients.9
The genes AKR1C1–4 and AKR1CL1 are clustered on chromosome
1018 (NCBI entry NC_000010.10) and localize as follows: AKR1C1,
5005454-5020158 (MIM 600449); AKR1C2, 5042103-5046053
(MIM 600450); AKR1C3, 5136568-5149878 (MIM 603966);
AKR1CL1, 5227144-5236924 ; AKR1C4, 5238798-5260912 (MIM
600451). The genes were amplified and sequenced with specific2, 2011
Figure 2. Identification of AKR1C2 Mutations in Families 1 and 2
(A) The pedigree of the index family (family 1). The AKR1C2 genotype and the amino acid exchange are given adjacent to the symbols.
Individuals II.4 and III.5 had a normal genotype, which is not indicated. Family generations are indicated in Roman numerals, and rele-
vant individuals within each generation are numbered. Individuals whose numbers are underlined were analyzed. Individual III.3
refused genetic testing (n.d. is an abbreviation for not done). The sexes indicated (a square for amale and a circle for a female) correspond
to the sex of rearing. The filled symbols represent individuals with a disorder of sexual development. The proband is individual III.2.
(B) Diagram of AKR1C2 on chromosomal region 10p14-p15 encoding 3a-HSD3. Coding exons 3–11 are shown as black boxes, noncod-
ing exons 1 and 2 are shown in gray. The locations of the four identified missense mutations are shown.
(C) High-resolution multipoint linkage analysis by GENEHUNTER (the model is based on autosomal-recessive transmission). For
markers D10S1713 and D10S2382, the maximum LOD scores were Z max ¼ 6.3 and 6.2, respectively.primers designed according to these entries. Three different
human AKR1C2mRNA transcripts are listed in the NCBI database,
but two of them (variant 1 NM_001354.4 and variant 2
NM_205845.1) differ only in their 50 untranslated regions and
encode the same protein (NP_001345.1, UniProt P52895). TheThe Americprimer sequences are reported in Tables S2 and S3. The third
splicing variant (NM_001135241.1) encodes the shorter protein
(isoform 2, NP_001128713.1, UniProt B4DKR9) with a different
C terminus; it has minimal 3a-hydroxysteroid dehydrogenase
(3a-HSD) activity and was not considered. The exon positionsan Journal of Human Genetics 89, 201–218, August 12, 2011 203
Figure 3. Analysis of AKR1C4 Transcripts
(A) The end-point reverse-transcriptase PCR anal-
ysis of AKR1C4 transcript from PBL of all avail-
able family members. In the affected members
of the family, the normally spliced AKR1C4
band (1194 bp) is present together with a shorter
band (1028 bp) that was shown by sequencing to
lack all of exon 2 (r.[ ¼ ];[r.85_252del]).
(B) An exon-trapping assay, demonstrating that
the mutation found in IVS1 (c.85-106G>T) re-
produced in COS1 cells, is responsible for the
aberrant splicing. The following abbreviations
are used: wt: cloned WT; mut: cloned mutant in
duplicate; Pat: patient: RT-PCR generated cDNAs
from PBL of Individual III.4. Black boxes repre-
sent the AKR1C4 exons; the white boxes are
vector sequences.
(C) Summary of the genetic findings in the index
family. Given the simultaneous presence of
the p.Ile79Val mutation in AKR1C2 and the
AKR1C4 splice mutation in all the cases, these
twomutations are expected to segregate together.and intron-exon boundaries of the AKR1C genes were checked by
BLAT analysis. For AKR1C2, DNA from 200 unrelated, healthy
individuals (180 white, ten Asians; eight blacks; two Hispanics)
and the 1000 Genome database were used as a control for poly-
morphisms. AKR1CL1 (NR_027916.1) produces a noncoding
RNA and was not considered for this study. Total RNA was
extracted from PBL of all family members (RNAeasy, QIAGEN
GmbH, Hilden, Germany) and used to perform end-point reverse
transcriptase PCR (RT-PCR) of AKR1C1–4 full-length cDNAs. RNAs
from 50 unrelated individuals were used as control.
For the patient in family 2, an additional long-range PCR
method was developed for the coding exons, with an AKR1C1
(NM_001353.5,) or an AKR1C2-specific forward primer (Table S2)
and the Expand 20kbPlus PCR System (Roche Applied Sciences).
Given the identity shared between the two genes in their 30
regions, the reverse primer is not specific. The two genes differ
in the number of EcoRI sites so that the EcoRI digestion of the
PCR product of AKR1C1 (3 sites) results in four main bands of
6.7, 5.5, 4.0, and 2.7 Kb, whereas digestion of AKR1C2 (4 sites)
results infivemainbandsof 6.0, 4.0, 3.1, 2.72, and1.8Kb (Figure3).
Splicing-Reporter Analysis
DNA fragments encompassing AKR1C4 (NM_001818.2 [MIM
600451]) exons 1 and 2 were amplified from patients’ and control
DNA and cloned into pCR3.1 (Invitrogen). Reporter constructs
were transfected into HeLA cells with the Fugene transfection
reagent. Forty-eight hours after transfection, cells were harvested,204 The American Journal of Human Genetics 89, 201–218, August 12, 2011and total RNA was extracted with an RNAeasy kit
(QIAGEN). The cDNAs were amplified with
vector-specific primers.19
Microsatellite Analysis
Microsatellite analysis for members of family 1
was performed with the ABI Prism Linkage
mapping set v 2.5 (811 markers, Applied Biosys-
tems) and a custom-made set of 17 microsatellite
markers for chromosome 10. Haplotypes were re-
constructed with the GENEHUNTER package
(Version 1.2). The disease gene frequency in thegeneral population was set at 0.0001.20 Two-point and multipoint
linkage analyses were performed by GENEHUNTER with the
affected-only allele-sharing method. SLink simulations were
done by the FASTLINK package21.
Computational Modeling and Docking Studies
We studied the effect of AKR1C2 mutations by structural
analysis to understand the consequences of specific amino acid
replacements on steroidogenic activities. A model of AKR1C2
(NP_001345.1) in a complex with 3a-androstanediol (3aDiol)
was built with YASARA22–24 and WHAT IF25. First, a 3D model of
3aDiol was built with ChemDraw and Chem3D and optimized
by energy minimization and molecular-dynamics (MD) simula-
tion in YASARA with the AMBER03 force field.26 The optimized
3aDiol was docked into the AKR1C2 structure with the program
Patchdock.27 We refined the docked structures by performing
MD simulations with YASARA dynamics.23,24 We ran MD simula-
tions with AMBER03 force field at 298 K and 0.9% NaCl in the
simulation cell for 500 ps to refine the docked structure. The posi-
tions of amino acids changed by mutations were evaluated for
possible contact with steroids or cofactors as well as structural
instabilities. Effects of mutations on binding of steroid substrates
to AKR1C2 were also evaluated by in silico analysis. To identify
the potential routes for binding of the steroid substrate, nicotin-
amide adenine dinucleotide phosphate (NADPþ) and the acetate
or citrate ions that sit between steroid and nicotinamide adenine
dinucleotide phosphate (NADPH) and facilitate the electron
transfer, we probed the AKR1C2 structure without the bound
steroids with the program Caver, which identifies tunnels in the
protein structures by connecting internal cavities with the
solvent.28 The shape of tunnels in AKR1C2 was approximated as
a pipeline originating from the acetate ion that was used as the
starting point for calculations. Distinct routes for binding of
steroid substrate and NADPH and a potential route for solvent
access for acetate or citrate ions was identified. Tunnels were de-
picted with a surface representation of the empty space and the
models were edited with the program Pymoland and depicted as
ray-traced images with POVRAY.
A 3D crystal structure of AKR1C4 (NP_001809.2) in complex
with NADPH is available (Protein Data Bank [PDB] number
2FVL) from the structural genomics consortium but has not
been described in a publication. We used the crystal structure of
AKR1C4 tomake a structural model of alternatively spliced variant
of AKR1C4 lacking exon 2. We built the model with YASARA by
using the structural alignment with full-length AKR1C4 and inde-
pendently modeling the N-terminal helix and joining it with the
rest of the structure. We modeled one loop (lndhFMPvlgfg) sepa-
rately by scanning the database of known loop structures. The
model was refined by MD simulation with the AMBER03 force
field as previously described.22–24,29Expression and Purification of Wild-Type
and Mutant AKR1C2
The bacterial expression vector pGEX-AKR1C2 containing wild-
type (WT) human AKR1C2 cDNA with an N-terminal gluta-
thione-S-transferase tag (GST) was a generous gift of Rock Breton,
Oncology and Molecular Endocrinology Research Center, Laval
University Medical Center, Quebec, Canada.30 Both the N and C
termini of AKR1C2 are important for steroid and cofactor binding;
therefore, the 972 bp AKR1C2 cDNA encoding the full-length
protein (NP_001345.1, 323 amino acids) was used in our studies.
Vectors for expression of the mutants were generated by PCR-
based site-directed mutagenesis with specific primers; all muta-
tions were confirmed by direct sequencing. Proteins were ex-
pressed in E. coli BL21(DE3)pLysS and then purified by glutathione
affinity chromatography as described.30 As a negative control, GST
was expressed from the empty pGEX vector and processed simi-
larly. The purity of the prepared proteins was assessed by SDS-poly-
acrylamide gel electrophoresis; Coomassie blue staining showed
single bands, and the purified proteins were quantitated colori-
metrically (Bio-Rad protein assay, Bio-Rad Laboratories GmbH,
Munich, Germany).In Vivo Activity of WT and Aberrantly Spliced
AKR1C4 in Cell Culture
WT or mutant AKR1C4 cDNA with an N-terminal Myc tag were
inserted into a pCMV6 vector and constructs were transfected
into ~80% confluent COS1 cells (ATCC CRL-1650) with TransFast
transfection reagent (Promega; 9 ml Transfast/mg DNA), and an
empty vector was used as the control. Transfection efficiency
was measured by transfecting with a vector containing pSV-
b-Galactosidase. Forty-eight hours after transfection, two 15 cm
plates were pooled for microsomal preparation as previously
described.31 Total protein content of the microsomal preparations
was measured with UniCel DxC600 (Beckman Coulter). Twelve
micrograms of microsomal protein (WT, Mut, and an empty
vector) were incubated with 0.0, 0.1, 1, 10, and 100 mM 5a-dihy-
droprogesterone (5a-DHP; Steraloids). In a second series of exper-The Americiments, 12 mg microsomal protein was incubated with 100 mM
DHP in the presence of 1, 10, and 100 mM and 1 mM NADPH or
nicotinamide adenine dinucleotide (NAD) for 45 min as
described.31 Subsequently, steroids were extracted with 0.8 ml
heptane and ethyl acetate (1:1, vol/vol), concentrated by evapora-
tion with N2 at 64
C, and assayed by gas chromatography fol-
lowed by mass spectrometry (GC/MS). The specific ion monitored
for 3aDiol (IS1) was 331.3; for stigmasterol (IS2), 394.3; for choles-
terol butyrate (IS3), 368.3; for 5a-DHP, 686; and for allopregnano-
lone, 474. Immunoblot analysis was performed with standard
procedures and an antibody against the Myc epitope (9E10, dilu-
tion 1:75).
Activity Assays of Human Recombinant WT
and Mutant AKR1C2
The catalytic activities of WT AKR1C2 and the three missense
mutations found in family 1 were assayed with two different
substrates. Oxidation of 3aDiol was assessed by incubating
10 mg recombinant AKR1C2 with 0.3–1000 mM [3H]3aDiol
(80,000cpm/reaction) and 1 mM NADþ in 50 mM KiP buffer
(K2HPO4/KH2PO4, pH7.4) in a final volume of 200 ml for 120 min
at 37C. Reduction of 5a-DHP was assessed with 3 mg recombinant
3a-HSD3, 0.1–100 mM [carbon 4-14C]5a-DHP (15,000cpm/reac-
tion), and 1 mM NADPH in the KiP buffer for 10–30 min at 37C.
Radiolabeled [3H]3aDiol was purchased from PerkinElmer AG
(Schwerzenbach, Switzerland). Radiolabeled [carbon 4-14C]5a-
DHP was a kind gift of Prof. Synthia H. Mellon (University of
California San Francisco, San Francisco, CA). The reactions were
stopped and the steroidswere extracted and separatedby thin-layer
chromatography as described8 and quantified by PhosphorImag-
ing (FLA-7000, Fujifilm AG, Dielsdorf, Switzerland). The Michaelis
constant (Km) and maximal velocity (Vmax) were calculated, and
Lineweaver-Burk plots were drawn computationally with Prism
(GraphPad Software, San Diego, CA, USA).
WT AKR1C2 and the c.666T>G (p.His222Gln) AKR1C2 mutant
found in family 2 were constructed in pCMV6 and transfected in
COS1 cells as described above for AKR1C4. Enzymatic activity in
microsomes was assessed with 0.0. 0.1, 1, 10, and 100 mM 3aDiol
(Steraloids). For the GC/MS measurements, ion monitoring was
131.3 for 3aDiol and 347 for DHT. In this case, 3aDiol was not
used as internal standard.
Fetal and Adult Expression of AKR1C1–4, AKR1CL1,
SRD5A1/2, and RoDH
Human fetal testes and adrenal cDNA were purchased from Bio-
chain (Amsbio, Lugano Switzerland, C1244260-10 and C1244004,
respectively). Normal adult testes and adrenals were kindly
provided by Prof. George Thalmann, University of Bern. cDNAs
from these tissues were prepared by total RNA extraction by the
Trizol method (Invitrogen, Basel, Switzerland) and reverse tran-
scription with the Improm RNA Transcriptase kit (Promega,
Madison, WI, USA) according to the manufacturer’s protocols.
Qualitative and quantitative real-time PCR experiments were
then performed on these cDNAs with primers specifically
recognizing the cDNAs of AKR1C1–4 and AKR1CL1 (AKR1C1,
NM_001353.5; AKR1C2, NM_001354.4; AKR1C3, NM_003739.4;
AKR1C4, NM_001818.3; AKR1CL1 alias AKR1E2, NR_027916),
SRD5A1-2 (SRD5A1, NM_001047.2 [MIM 184753]; SRD5A2,
NM_00348.3 [MIM607306]) and RoDH (HSD17B6, NM_003725.2).
The identities of the end-point reverse transcriptase-PCR products
were confirmed by sequencing. Quantitative real-time PCR was
performed with the same primers and quantified as described.32an Journal of Human Genetics 89, 201–218, August 12, 2011 205
In brief, real-time PCR, performed with an ABI 7000 Sequence
Detection System (Applera Europe) and PCR products were
quantified fluorometrically with the SYBR Green Core Reagent kit.
The reference mRNA cyclophillin was used for normalizing the
data (the primers are listed in Table S4). The relative expression
was calculated with the 2DDCt method. Statistical analysis was per-
formed with a two-tailed t test (confidence interval 95%) with
GraphPad Prism software.Results
Clinical Genetics in Family 1
In 1972 a Swiss family with a 17,20-desmolase defi-
ciency17, now termed 17,20 lyase deficiency’’(MIM
202110), was described. Two 46,XY cousins (Figure 2,
III.3, III.4) had cryptorchidism and undervirilized external
genitalia at birth and hormonal evidence of defective
androgen synthesis. The maternal aunt (II.5) had 46,XY
sex reversal and similar steroid hormone abnormalities.
We sought to determine the genetic defect in these indi-
viduals; the family agreed to genetic testing but refused
all further hormonal testing, hence the only hormonal
data available are those from 1972. Steroid 17a-hydroxy-
lase and 17,20 lyase activities are catalyzed by P450c17
and encoded by CYP17A1;33–35 the 17,20 lyase activity
of P450c17 requires electron donation from P450 oxidore-
ductase and the allosteric assistance of cytochrome b5.
8
The hormonal findings of isolated 17,20-lyase deficiency
might result from specific mutations in CYP17A136 or
POR37 and by absence of cytochrome b5.
38 Sequencing
of CYP17A1, POR, NR5A1 (steroidogenic factor-1), CYB5
(cytochrome b5), and NR3C4 (an AR) revealed no muta-
tions in these subjects, and the available hormonal data
suggested no defects in 17b-hydroxysteroid dehydroge-
nase or 5a-reductase activities. Therefore, we considered
whether mutations in genes for factors specific to the
alternative pathway for production of DHT might be
involved. This pathway entails both oxidative and reduc-
tive 3a-HSD reactions, which are not components of the
classic pathway (Figure 1). Available evidence indicates
that the reductive reaction is catalyzed by AKR1C2,39,40
although the involvement of other members of the
AKR1C family is also possible. The enzyme catalyzing
the oxidative reaction is less clear, although 3-hydroxyepi-
merase (HSD17B6, also known as RoDH) has oxidative
3a-HSD activities and converts androstanediol to DHT
in the prostate;41 another candidate might be
AKR1C4.42,43
Sequencing of the exons of the 31 kb AKR1C2 gene iden-
tified missense mutations in all affected individuals (Fig-
ures 2A and 2B). Individual II.5 was a compound heterozy-
gote for the AKR1C2 missense mutations c.235A>G
(p.Ile79Val) and c.270T>G (p.His90Gln), and individual
III.2 was compound heterozygous for c.235A>G and
c.899A>C (p.Asn300Thr); individual III.3 declined genetic
testing (Figure 2A). All affected individuals had a 46,XY
karyotype; 46,XX individual II.2 was a compound hetero-206 The American Journal of Human Genetics 89, 201–218, August 1zygote for AKR1C2 mutations c.235A>G and c.270T>G
(p.His90Gln), as was affected individual II.5, yet she was
phenotypically normal and bore three children. Thus, in
this family, the consequences of AKR1C2 mutations were
a sex-limited autosomal-recessive trait. These genetics are
consistent with androgens playing no essential role in
female sexual development. AKR1C2 heterozygosity in
46,XY individual II.1 was associated with normal genital
development and normal reproductive capacity, and
heterozygous 46,XX individual II.3 was phenotypically
normal and fertile. The external genitalia in 46,XY individ-
uals II.5 and III.2 were severely undervirilized, and these
individuals had been assigned a female sex at birth. By
contrast, heterozygous individual III.4 was reported to be
moderately undervirilized (Prader 3 genitalia with unde-
scended testes and a microphallus) and to be hormonally
similar to individual III.3,17 who refused genetic testing.
To address the possibility that these missense mutations
were polymorphisms, we sequenced AKR1C2 in 200 unre-
lated, healthy individuals (180 whites, ten Asians, eight
blacks, and two Hispanics) and found no mutations in
these 400 alleles. None of the mutations is present in the
1000 Genomes database (location browsed was chromo-
some 10: 5042103-5046053).
To confirm that the mutations in AKR1C2 are respon-
sible for the phenotype in family 1, we scanned the whole
genomes of nine individuals in generations II and III with
811 microsatellite markers (Figure S1). Multipoint
affected-only allele-sharing methods suggested potential
linkage to chromosomes 10 and 22 with LOD scores
higher than 2.2 (genome-wide suggestive linkage LOD
2.2). Therefore, we re-examined these chromosomes with
custom-made primers to probe microsatellites on 10p
and 22q at higher resolution. On chromosomal region
22q12, D22S1167 and D22S1144 gave LOD scores of 3.2;
D22S1167 had no cross references, whereas D22S1144 is
linked to an insulinoma tumor suppressor gene (ITS
[MIM 606960]), a sensorineural hearing loss gene
(DFNB4 [MIM 600791]), and a gene for familial partial
epilepsy syndrome (FPEVF [MIM 604364]). None of these
genes appears to be involved with steroidogenesis. On
chromosomal region 10p15, D10S1713 and D10S2382
gave scores of 6.3 and 6.2, respectively. These two markers
span a region of about 0.5 Mb containing AKR1C1–4. No
other signals were detected; in particular, signals were
not found at the chromosomal loci encoding microsomal
cytochrome b5 (CYB5A [MIM 613218]) (18q23), mito-
chondrial b5 (CYB5B [MIM 611964]) (16q22.1), 5a-reduc-
tase type 1 (SRD5A1; 5p15), and RoDH (HSD17B6)
(12q13.3) (Figure S1), confirming our identification of
a disordered AKR1C enzyme in this family (Figure 2C
and Figure S1). Because other members of the AKR1C
family might also catalyze 3a-HSD reactions and the
microsatellite analysis could not distinguish these closely
linked genes, we also sequenced AKR1C1, AKR1C3,
AKR1C4, and AKR1CL1 from individual III.2 but found
no mutations in the coding regions.2, 2011
Splicing Analysis
Because the exonic sequencing could not exclude splicing
mutations, we studied the splicing pattern of these five
AKR1Cs by analyzing cDNA amplified from reverse tran-
scribed mRNAs extracted from PBL of all the family
members. AKR1C1, AKR1C2, AKR1C3, and AKR1CL1 were
normally spliced, whereas AKR1C4 showed an aberrantly
spliced fragment in individuals II.2, II.3, II.5, III.2, and
III.4, in addition to normally splicedmRNAs (cDNA) (r.[¼ ];
[85_252del], Figure 3A). Direct sequencing showed that
exon 2 was completely absent from the aberrantly spliced
AKR1C4. Sequencing of the flanking introns (IVS) identi-
fied a heterozygote G to T substitution 106 bp upstream
of exon 2 (c.[ ¼ ]; [85-106G>T]). An exon trapping assay
demonstrated that this IVS mutation resulted in loss of
exon 2 (c.85_252del) (Figure 3B). The splicing mutation is
in frame and is expected to delete AKR1C4 residues 29–84
(p.Val29_Lys84del). No aberrant splicing was found in 50
normal controls. Given the simultaneous presence of the
p.Ile79Val mutation in AKR1C2 and the AKR1C4 splice
mutation in all the cases, these twomutations are expected
to segregate together (Figure 3C).
Clinical Genetics in Family 2
Family 2 was studied after the AKR1C mutations had been
identified in family 1 so that investigation quickly focused
on the AKR1C locus in family 2. This patient carried a
complex rearrangement that was apparently due to an
unequal crossover between AKR1C2 and the neighboring
AKR1C1, which share about 90% sequence identity.
Long-range PCR of AKR1C1 and AKR1C2 followed by
EcoRI digestion of the 18 kb products distinguished these
two genes (Figure 4A). The normal array of EcoRI products
is seen in the two parents, but the patient has bands typical
of AKR1C1 and AKR1C2 (Figure 4B), suggesting a recombi-
nation between the two genes in which a hybrid AKR1C1/
AKR1C2 containing the first three coding exons of AKR1C1
was fused to the 30-terminal exons of AKR1C2. This was
confirmed by reamplification and sequencing of the
AKR1C2-specific 18 kb band with AKR1C1-specific internal
reverse primers (Figure 4C). Thus the patient has a single
AKR1C1/AKR1C2 hybrid on allele 1 and paternal
AKR1C1, AKR1C1/AKR1C2, and maternal AKR1C2 genes
on allele 2; this cluster spans>85 kb (Figure 4D). The intact
maternal AKR1C2 on allele 2 carries a missense mutation
in exon 9 (the sixth coding exon) (c.666T>G), and the
paternal copy of AKR1C1 carries no mutation (Figures 4B
and 4D). On allele 1, no mutation was found in the exons
of either the AKR1C1 or AKR1C2. AKR1C4 carried nomuta-
tions in this patient (not shown). A diagram of the putative
unequal crossover leading to the rearrangement found in
the patient is shown in Figure 4E.
AKR1C2 Modeling Studies
The AKR family of enzymes have very similar amino acid
sequences, and most catalytically important residues are
conserved (Figure 5A and Figure S2). AKR1C2 acts on struc-The Americturally diverse steroids, such as androgens and progestins,
and can bind numerous nonsteroidal molecules through
an induced-fit mechanism.30 To investigate its functional
plasticity, we built a structural model of AKR1C2 based on
the crystallographic structure of human AKR1C244–48 and
docked 3aDiol into the structure (Figure 5B). The
substrate-binding pocket of AKR1C2 consists mainly of
loops and is therefore quite flexible, allowing the binding
of different substrates. Two of the amino acids, Ile79 and
Asn300, that were mutated in our patients are at the begin-
ning of loops that make up the steroid-binding pocket
(Figure 5B); amino acid changes at these locations might
disturb the Lys84, Trp86, and Leu308 residues further
down the loops that interact with the substrates at the cata-
lytic site. The His90 residue that was found to bemutated is
in close proximity (5.2A˚) to His117 and in contact with
Ile116 and Phe118, which are part of catalytic center. In
our analysis, the His117-NADPH contact was broken in
theHis90Gln variant, potentially from the additional inter-
actions of Gln90 with side chains of neighboring residues.
His117 is essential for the activity in all AKR family
members (Figure S2); it interacts with a central acidic ion
to act as a bridge between steroid substrate and NADPH. A
change in interaction between NADPH and His117 will
likely affect cofactor binding and electron transfer.
The p.His222Gln mutation elicited intriguing structural
changes in the AKR1C2 structure. His222 is situated in the
middle of a loop that appears to be involved in binding
both the steroid substrate and the cofactors. Earlier anal-
ysis comparing the rat and human AKR1C2 structures
has shown that change of His222 to Ser222 in the
AKR1C2 causes structural changes by pushing the side-
chain of neighboring Trp227, resulting in structural
constraints on steroid binding at the catalytic center.47
We found that the substitution of His for Gln, as found
in our patient, does not shift the side-chain of Trp227, so
that the steroid-binding pocket remains unchanged.
However, analysis with Caver program indicates that flip-
ping of the side-chain of Gln222 pushed it into the
NADPH-binding tunnel, potentially blocking NADPH
entry (Figures 5B and 5C and Figure S2). In
human AKR1C3 and AKR1C4, His222 is naturally replaced
Gln222 (Figure S2), but unlike in AKR1C2, this change
is accommodated in both of these enzymes by other
amino acid replacements (as compared to AKR1C2) that
could alter the cofactor-binding patterns (Figure S2). A
major factor in AKR1C2 reactions is the release of cofactors
after catalysis; minor changes in charge caused by
p.Asn300Thr could influence how a particular steroid or
cofactor could exit the catalytic site. An enzyme with
slower release of product or cofactor will impair binding
of the next molecule of substrate or the cofactors.
Effect of Alternate Splicing on Structure of AKR1C4
The amino acid sequence of AKR1C4 is very similar to
AKR1C2, and most of the catalytically important residues
(Asp50, Tyr55, Lys84, and His117) are found in similaran Journal of Human Genetics 89, 201–218, August 12, 2011 207
Figure 4. Identification of AKR1C2 Mutations in Family 2
(A) A schematic representation of the genomic organization of AKR1C1 (red), the intervening sequence (black), and AKR1C2 (blue) on
chromosome 10. The vertical lines represent EcoRI (E) recognition sites. The expected EcoRI fragments and their relative locations are
represented by black lines. Primers are indicated by arrows: red for AKR1C1-specific, blue for AKR1C2-specific, and black for nonspecific.
(B) Upper Panel: long-range PCR. The PCR products using the AKR1C1 primers yield an unexpected band of 85 kb in addition to the
expected band of 18 kb, as also seen with the AKR1C2 primers. The 85 kb product suggests a complex recombination between
AKR1C1 and AKR1C2 in the patient. Lower Panel: EcoRI digestion of the long-range PCR. The colored markers to the left indicate the
bands derived from AKR1C1 (red), AKR1C2 (blue), or both (black). The 4.9 bp band indicated by the gray line likely derives from the
AKR1C1/AKR1C2 junction. Because the PCR used an end-point amplification method, the intensity of the bands does not allow any
quantitative (copy-number) conclusion.
(C) Sequencing demonstrating the presence of the missense mutation c.666T>G in the patient’s AKR1C2 gene inherited from the
mother.
(D) Putative scheme of long-range PCR and EcoRI digestion of PCR products from genomic DNA with either AKR1C1-specific (red) or
AKR1C2-specific (blue) primers as derived by the results in (B).
(E) A diagram of the putative unequal crossover leading to the rearrangement found in the patient. The p.His222Gln mutation is indi-
cated by the bright yellow lesion in the downstream portion of AKR1C2.positions in both enzymes (Figure 5A). Binding and release
of both NADPH and steroid substrates require significant
flexibility in the AKR1C4 structure (Figure 5D). Analysis
of MD simulation revealed movements of short flexible208 The American Journal of Human Genetics 89, 201–218, August 1fragments that comprise amino acids 9–14 and 50–59,
and open and close access to the catalytic center. To study
the effect of deleting exon 2, wemade a structural model of
AKR1C4 lacking the 56 amino acids (Val29-Lys84) encoded2, 2011
by exon 2. Deletion of exon 2 results in a stable structure
that should bind NADPH (Figure 5E), but several catalyti-
cally essential residues are missing, which would render
the truncated mutant inactive. In both AKR1C2 and
AKR1C4 an active site tyrosine (Tyr55) acts as catalytic
center that is missing in the alternatively spliced variant
of AKR1C4 (Figure 5E). In addition, three other amino
acids that are part of the catalytic center, Asp50, Leu54,
and Lys84 aremissing from the truncated AKR1C4mutant.
In AKR1C4, Leu54 is potentially involved in determining
substrate specificity, and Asp50 and Lys84 together balance
the pKa of the active site, which is necessary for transfer-
ring electrons from NADPH to the steroid substrate
(Figure 5F). The missing residues in the AKR1C4 catalytic
center would prohibit steroid substrates from binding in
the correct orientation for the enzymatic reaction,
rendering the exon 2 deficient variant of AKR1C4 catalyt-
ically inactive or grossly impaired compared to the WT
enzyme.
Enzymology of the Identified AKR1C2 Mutants
WT and mutant AKR1C2 proteins were expressed in
bacteria, purified to apparent homogeneity, and their
activities were characterized in vitro with substrates that
are part of the alternative pathway but not the classic
pathway (Figure 6). AKR1C enzymes catalyze both oxida-
tive and reductive reactions, depending on cofactor
availability; oxidative reactions require NADþ, whereas
reductive reactions require NADPH (Figure 6A).49 In the
alternative pathway, AKR1C2 catalyzes the reduction of
5a-DHP (for systematic names, see the legend to Figure 1)
to allopregnanolone (allo) and the reduction of 17-
hydroxy-dihydroprogesterone (17OH-DHP) to 17OH-allo;
AKR1C2 might also hypothetically catalyze the oxidation
of 3a-androstanediol (3aDiol) to dihydrotestosterone
(DHT). However, the AKR1C enzymes have very high
affinity for NADP(H) (Kd ¼ 100–200 nM) and low affinity
for NAD(H) (Kd¼ 200 mM), making NADP(H) the preferred
cofactor in vivo, so that AKR1C2 should function primarily
as a reductase. When transfected into COS-1 cells and
forced to use the prevailing concentration of the cofactor,
AKR1C2 functions only as a 3-ketosteroidreductase,40 and
when 1 mM NADþ is supplied to recombinant AKR1C2
in vitro so that it permits oxidation of 3aDiol to DHT,
the reaction can be blocked by only 10 mM NADPH.40,50
Thus AKR1C2 is expected to function almost exclusively
as a reductive 3a-HSD. Consistent with this cofactor
requirement, other members of the AKR1C family do not
oxidize 3aDiol effectively,42 although in vitro AKR1C4
can oxidize 3aDiol to DHT.43,51 The AKR1C2 mutants
Ile79Val, His90Gln and Asn300Thr had reduced activities
in our functional assays. In the presence of 1 mM NADþ,
the capacity (Vmax/Km) of AKR1C2 to oxidize 3aDiol to
DHT was reduced to 28%–49% of WT control for the four
mutants; in the presence of 1 mM NADPH, the capacity
of AKR1C2 to reduce 5a-DHP to allo was reduced to
22%–82% of WT control (Figure 6 and Table 1).The AmericGC/MS assays of steroids produced by cells expressing
WT and the His222Gln mutant showed that WT readily
converted 100 mM 3aDiol to DHT, but cells expressing
the mutant His222Gln had dramatically reduced ability
to produce DHT (Figure 7A). Immunoblotting suggested
that there were no differences in the quantity or stability
of the WT and truncated proteins (Figure 7B, inset). In
microsomes from COS1 cells, the mutant had no detect-
able activity, whereas the WT had a Michaelis constant
(Km) of 5.4 mM and a maximum velocity (Vmax) of 350
pg/min/mg protein (Figure 7C). Thus, the identified
AKR1C2 mutations partially impair the 3a-HSD activity
of AKR1C2 but not to the degree typically associated
with recessive disorders of steroidogenesis.
Enzyme Activity of the Identified Aberrantly Spliced
AKR1C4 In Vivo
The activity of AKR1C4 to convert 5a-DHP to allo was
determined in transiently transfected COS1 cells. As as-
sayed by GC/MS, cells expressing WTAKR1C4 readily con-
verted 100 mM5a-DHP to allo (Figure 8A), but cells express-
ing the truncated mutant had only about 10% of WT
activity (Figures 8B and 8C). Immunoblotting suggested
that there were no differences in the quantity or stability
of the WT and truncated proteins, although the mutant
protein was shorter, as expected (Figure 8C, inset). Conver-
sion of 5a-DHP to allo was also measured in microsomes
from COS1 cells expressing the WT or mutant AKR1C4;
this permitted calculation of the apparent Michaelis
constant and maximum velocity and showed the mutant
was essentially devoid of activity (Figure 8D). Addition of
NADPH (but not NAD) increased DHP reduction by the
WT AKR1C4 in a dose-dependent manner, but addition
of NADPH or NAD had no effect on the truncated mutant
(Figure 8E). We found no detectable oxidation of allopreg-
nanolone to 5a-DHP by WT AKR1C4 (not shown).
Tissue Distribution
To characterize the role of AKR1C2 in fetal DHT produc-
tion, we performed quantitative RT-PCR expression profil-
ing of AKR1C and SRD5A in normal fetal and adult testes
and normal fetal and adult adrenal tissues (Figure 9).
AKR1C2 cDNA could be readily amplified from fetal but
not adult testes (Figure 9A), whereas SRD5A2was expressed
at lower levels in fetal than in adult testes (Figure 9B).
AKR1C4 is also expressed in fetal (and adult) testes
although at lower levels. RoDH was abundantly expressed
in the control human liver HepG2 cells, and low but
detectable amounts of RoDH were detected in the fetal
testes (Figure 9C). Thus the role of RoDH as a potential
oxidative enzyme converting 3a-HSD to DHT in the testic-
ular alternative pathway to DHT is probable but not
proven. Adult adrenals expressed markedly more AKR1C2
than fetal adrenals (Figure 9D), so that the alternative
pathway to DHT production might not be a significant
pathway in the fetal adrenal but might be important in
the adult adrenal, especially in situations where 17OHPan Journal of Human Genetics 89, 201–218, August 12, 2011 209
Figure 5. Structural Biology of AKR1C2 and AKR1C4
(A) Amino acid sequences of human AKR1C2 and AKR1C4. Mutations causing amino acid changes (p.Ile79Val, p.His90Gln, and
p.Asn300Thr) in AKR1C2 are marked with red arrows and positions of active site residues are marked in gray (Asp50, Tyr55, Lys84,
and His117). For AKR1C4, the major active site residues are marked and the position of amino acids encoded by exon 2 is shown
with a green bar. Amino acids are colored based on charge; acidic residues (Asp, Glu) are in red, basic residues (His, Arg, Lys) are in
blue and the rest of the polar amino acids (Asn, Cys, Ser, Thr, Tyr) are in green.
(B) Amodel of AKR1C2with docking of 3aDiol. An acetatemolecule between 3aDiol and NADPH facilitates electron transfer. Tunnels or
binding pockets for NADPH (blue), 3aDiol (red) and acetate (green) are shown as transparent surface models. The amino acid mutations
found in the patients are depicted as ball-and-stick models (red); the docked 3aDiol (magenta) and NADPH (blue) are shown as stick
models and the acetate molecule is shown as a sphere model (green). The substrate-binding pocket of AKR1C consists of mainly flexible
loops. Changing amino acids Ile79 and Asn300, which are at the beginning of the loops that comprise the steroid-binding pocket, might
210 The American Journal of Human Genetics 89, 201–218, August 12, 2011
Figure 6. Assessment of AKR1C2 Activities
(A) Enzymatic reactions catalyzed by AKR1C2
that were assayed in vitro. AKR1C2 catalyzes
the reduction of 5a-DHP (5a-pregnane-3,20-
dione) to allopregnanolone (5a-pregnane-3a-ol-
20-one) in the alternative pathway. AKR1C2
also supports the oxidation of 3aDiol to dihydro-
testosterone in vitro.
(B) SDS-PAGE of the bacterially expressed, puri-
fied proteins used for enzymatic assays.
(C and D) Lineweaver-Burk plots of activities of
WT and mutant AKR1C2 proteins. (C) Reduction
of different concentrations of radiolabeled
5a-DHP to allopregnanolone in the presence of
1 mM NADPH. (D) Oxidation of androstanediol
to DHT in the presence of 1 mM NADþ.concentrations are high, such as in congenital adrenal
hyperplasia from 21-hydroxylase deficiency. Taken
together, these data support a role of AKR1C2 and
AKR1C4 in DHT production in the fetal testis.Discussion
AKR1C1–4 on chromosomal region 10p14-p15 encode
four enzymes belonging to a family of 15 aldo-keto reduc-
tases. These four AKR1Cs share high sequence similarity
and act as ketosteroid reductases and hydroxysteroid
oxidases.18,52–54 Whereas all four AKR1Cs act as 3-, 17-,
and 20-ketosteroid reductases, only AKR1C2 and AKR1C4
can oxidize 3aDiol to DHT in vitro,55 and AKR1C2 isdisturb the orientation of Trp86 and Leu308 (shown as orange ball-and-stick models
Residue His222 is involved in interaction with the steroid substrates, and the cofacto
chain of Gln222 blocking the NADPH-binding site. The catalytically important Tyr5
models. The AKR1C2 structure is shown as a ribbon model with rainbow colors sta
with red at the C terminus.
(C) A detailed view of the side chains of His222 and Gln222. The His222Gln mutatio
and the mutated structure was aligned with the WT structure. The His222Gln mutatio
blocks the path of the NADPH-binding tunnel. The His222 (green) and Gln222 (red) re
(blue) is shown as a ball-and-stick model and the central acetate ion found in the AKR
(D) The crystal structure of AKR1C4 (PDB number 2fvl chain c) shown as a ribbonsmod
the substrate-binding site is blocked. However, most of the substrate and/or cofact
showed variable positions during MD simulations.
(E) A model of the product of AKR1C4 lacking exon 2. The model was based on the c
lacking exon 2, most of the core structure is still intact, but the first two N-terminal he
and have been replaced by a single helix at the start of the N terminus.
(F) A close-up of the active site of AKR1C4. The catalytically important residues are sh
the catalytic tetrad (Asp50, Tyr55, and Leu84) plus the active site residue Leu54 that i
AKR1C4 lacking exon 2. Catalytic center components are shown as sticks with act
magenta, Lys84 in blue, His117 in green, and NADPH is in cyan.
The American Journal of Hummore efficient.51 AKR1C2 uses NADþ as its
cofactor for oxidative reactions and NADPH
for reductive reactions. AKR1C2 can bind
steroids in multiple orientations, providing
exceptional flexibility for multiple sub-
strates and types of reactions catalyzed.
The relative abundances of the cofactors
available in different tissues thus governs
the direction of AKR1C2 catalysis. In mostcells, NAD and NADH are ~10-fold more abundant than
NADP and up to 1000-fold higher than NADPH,56,57
and this makes AKR1C2 primarily a reductive enzyme.
Low levels of NADP and NADPH should favor oxidative
reactions of AKR1C2 and conversion of 3aDiol to DHT.
Of the AKR1C enzymes, AKR1C4 is catalytically the
most efficient, is most abundant in the adult liver, and
is thought to work in concert with the 5a/5b reductases
to protect the liver from excess steroid hormones.51
AKR1C4 is also expressed in rat testis and adrenals.58
In a family having several members with 46,XY DSD, we
found linkage to the region of chromosome 10 containing
the five AKR1Cs and found mutations in the coding region
of AKR1C2 and a splicing mutation in AKR1C4. Inheri-
tance was sex-limited recessive, as 46,XY individuals had) that interact with a steroid at the catalytic site.
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Table 1. Activities of WT and Mutant AKR1C2
Enzyme Substrate Km Vmax
Intrinsic clearance
Vmax/Km (% of WT) Reaction Type
WT 3aDiol 38.17 5 0.49 3.89 5 0.8 0.104 (100) oxidation
p.Ile79Val 3aDiol 32.52 5 1.10 1.62 5 0.71 0.050 (48) oxidation
p.His90Gln 3aDiol 20.56 5 0.83 0.87 5 0.29 0.042 (41) oxidation
p.Asn300Thr 3aDiol 22.23 5 1.24 0.87 5 0.43 0.039 (28) oxidation
WT 5a-DHP 11.62 5 0.06 18.7 5 4.2 1.61 (100) reduction
p.Ile79Val 5a-DHP 15.31 5 0.08 20.3 5 7.9 1.32 (82) reduction
p.His90Gln 5a-DHP 15.17 5 0.11 5.4 5 2.5 0.36 (22) reduction
p.Asn300Thr 5a-DHP 24.22 5 0.09 16.0 5 6.0 0.66 (41) reduction
Km is measured in mM, and Vmax is measured in nmol/min/mg protein. The following abbreviations are used: 3aDiol, androstanediol; 5a-DHP, 5a-pregnane-3,20-
dione (5a-dihydroprogesterone).DSD but the genetically affected 46,XX individuals were
phenotypically normal and fertile. These observations
confirm that androgens, especially DHT, are not necessary
for female sexual development; these findings are similar
to those in women with SRD5A2 mutations. Two observa-
tions were puzzling. First, the AKR1C2 mutations caused
a milder reduction in activity than that usually found in
recessive disorders of steroidogenesis. Second, heterozy-
gous 46,XY individuals had divergent phenotypes: indi-
vidual II.1 was normal and fertile, whereas III.4 had DSD.
This suggested the presence of a second hit. After
excluding coding mutations in the other linked AKR1Cs
on chromosome 10, we sought aberrant splicing, which
could account for up to 50% of all functional muta-
tions.59 AKR1C4was aberrantly spliced in the affected indi-
viduals, leading to loss of key amino acids in the translated
protein that reduced enzyme activity as assessed in expres-
sion studies. The presence of loss-of-function mutations in
two closely linked genes indicates that mutations in both
loci were needed to cause disease in family 1. Similar exam-
ples of such digenic inheritance are known, including
holoprosencephaly (MIM 236100)60 and cortisone reduc-
tase deficiency (MIM 604931), a triallelic, digenic defect
of steroidogenesis.61 Thus family 1 appears to exhibit
synergistic heterozygosity62 in which mutations in more
than one gene in a pathway give rise to a phenotype,
whereas a defect in only one gene is insufficient to cause
disease.60 Thus the effect of these mutations is cumulative,
as the phenotype is more severe with an increasing
number of mutations (see individual III.2 versus individual
III.4).
Although it appears that a phenotype occurs in family 1
only if mutations in both AKR1C2 and AKR1C4 are
present, all mutations identified in this family retained
partial activity, so that the relative importance of
AKR1C2 and AKR1C4 was uncertain. The presence of
AKR1C2 mutations without AKR1C4 mutations in the
patient with 46,XY DSD from family 2, and the absence
of AKR1C4 mutations in 33 other patients with 46,XY212 The American Journal of Human Genetics 89, 201–218, August 1DSD (M.M-B and A.B-L, unpublished data) indicates that
AKR1C2 mutation is sufficient for disease manifestation
and suggests that AKR1C2 could serve a more important
role than AKR1C4 for this form of DSD.
Genetic 46,XY males lacking AR activity have female
external genitalia, establishing the essential role of andro-
gen action in male genital development.63 Two androgens
are involved, testosterone and its more potent derivative,
DHT, acting through a single AR.64 Testosterone is
produced by fetal and adult testicular Leydig cells and is
converted to DHT in target tissues, such as fetal genital
skin, by SRD5A2.2,65 The complete absence of SRD5A2
activity does not yield the female phenotype seen when
AR is absent but instead leads to incompletely developed
male genitalia;66 this partial virilization has been attrib-
uted to the action of testicular testosterone because DHT
synthesis was thought to be confined to extratesticular
sites.67 Our finding that AKR1C2 and AKR1C4 are ex-
pressed in fetal testes but are barely detectable in adult
testes is consistent with a crucial role for these AKR1C
enzymes in fetal male development, despite the miniscule
quantities of DHT found in adult spermatic vein blood.68 It
appears that both AKR1C2 and AKR1C4 function as reduc-
tive 3a-HSD enzymes, and HSD17B6 functions as the
oxidative enzyme; however, further work is needed to
delineate the precise roles of these enzymes in the human
fetus. Assuming that wallaby, mouse, and human path-
ways are comparable, 5a-DHP, which needs to be reduced
to allopregnanolone for the synthesis of 3aDiol, is the
key intermediate in the alternative/backdoor pathway.
Thus, both AKR1C4 and AKR1C2 appear to be needed for
synthesis of DHT in the backdoor pathway of the fetal
testis. The roles of the relative abundances of oxidative
NAD and reductive NADPH in the fetal testis remain
unclear. The regulation of NAD kinase, which converts
NAD to NADP,69 might control this ratio.
Thus fetal deficiencies of AKR1C2 and AKR1C4 cause
a phenotype similar to that associated with deficiencies
of SRD5A2 or P450c17 (17,20 lyase activity), indicating2, 2011
Figure 7. Assessment of AKR1C2 Mutant Enzymatic Activity in Family 2
(A) Steroid identification by gas chromatography. Extracts from COS1 cells transiently transfected with WT or mutant AKR1C2 cDNAs
were challenged with 100 mM3aDiol for 6 hr, and the resulting steroids in the culturemediumwere identified bymass spectrometry. The
following abbreviations are used: AN, 3aDiol; DHT, dihydrotestosterone; internal standard A (ISA) ¼ pregnanediol (PD); Internal stan-
dard B (ISB) ¼ tetrahydro-11-deoxycortisol (THS).
(B) Immunoblotting of WT and p.His222Gln AKR1C2.
(C) Catalytic activity of the AKR1C2 p.His222Glnmutant. Quantification of DHT inmicrosomes fromCOS1 cells transiently transfected
with WT or mutant AKR1C2 cDNAs and exposed to different concentrations of 3aDiol as in (A). The calculated Vmax and Km are
depicted (mean5 standard deviation [SD] data from three independent experiments).that the fetal testis secretes DHT synthesized via the
alternative pathway without the intermediacy of testos-
terone. The presence of the alternative pathway in the
marsupial,6,70 rodent,71 and human fetal testes indicates
that the use of two pathways of androgen biosynthesis isThe America general mammalian feature. Because defects in both
the classical and alternative pathways of DHT synthesis
cause similar phenotypes, it now appears that both
pathways are essential to normal human male genital
development.an Journal of Human Genetics 89, 201–218, August 12, 2011 213
Figure 8. Assessment of AKR1C4 Reductive Activity
(A and B) Steroid identification by gas chromatography. Extracts from COS1 cells transiently transfected with WT (A) or mutant (B)
AKR1C4 cDNAs were challenged with 100 mM 5a-DHP for 6 hr. Individual steroids were identified by mass spectrometry; internal stan-
dard (IS): 1 ¼ androstanediol; 2 ¼ stigmasterol; 3 ¼ cholesterol butyrate. A representative experiment is shown.
(C) Quantification of the product allopregnanolone in intact COS1 cells transfected with normal (WT), mutant (aberrantly spliced,Mut),
and empty vectors exposed to 100 mM5a-DHP. Inset: Immunoblotting showing no differences in the amount or stability ofWTandMut
AKR1C4 loaded in two different amounts (one representative experiment out of three is shown). The mutant protein, lacking 56 AA, is
shorter than the WT. b-act is an abbreviation for b-actin. The data are from three independent experiments (mean5 SD).
(D) Quantification of allopregnanolone inmicrosomes of COS1 cells treated as in (C) and exposed to different concentrations of 5a-DHP.
The calculated Vmax and Km are depicted (mean5 SD data from three independent experiments).
(E) Allopregnanolone formation by microsomes from COS1 cells transfected with vectors for either WT (black) or mutant (red) AKR1C4
or empty vector (gray). The microsomes were incubated with 100 mM 5a-DHP and exposed to increasing amounts of NADPH (reductive)
or NAD (oxidative) cofactors. Data are mean5 SD of three independent experiments.Supplemental Data
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Figure 9. Quantitative RT-PCR Assessment of AKR1C1–4 and AKR1CL1, SRD5A1–2, and RoDH Expression in Normal Fetal and Adult
Testes and Adrenals
(A) Expression of AKR1C1 and C2 in normal fetal versus adult testes and in human liver HepG2 cells (the positive control). AKR1C2 is
expressed at high levels in fetal but very low levels in adult testes. In adult testes, AKR1C1 seems to be the predominant AKR1C, followed
by AKR1C4, whereas C2, C3, and CL1 are expressed at similar lower levels.
(B) SRD5A2 is expressed at low levels in fetal testes but is highly expressed in adult testes. SRD5A1 expression is lower in adult than fetal
testes.
(C) Compared to AKR1C2, RoDH is expressed at very low levels in the fetal testes, even lower than SRD5A2. The other four AKR1Cs (1, 3,
and 4 and AKR1CL1) are expressed at similar levels but are significantly lower than AKR1C2.
(D) Normal fetal adrenals express very little AKR1C2; low levels of AKR1C1, AKR1C3, and AKR1CL1; and abundant AKR1C4. By contrast,
the adult adrenals express all AKR1Cs; AKR1C1 at a lower level; and AKR1C2, AKR1C3, AKR1C4, and AKR1CL1 at similar levels. ***p <
0.0005, **p < 0.005, *p < 0.05. ns is an abbreviation for not significant.to A.B.L.). We thank Rock Breton for providing the human WT
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